Most head and neck squamous cell carcinoma (HNSCC) cases are diagnosed late, with an increased risk of recurrence and distant metastasis. In recent years, there has been a surge in the development of ...

Discover expert insights on head and neck cancer trial updates, including the efficacy of amivantamab and pembrolizumab ...

Prognosis is extremely poor for patients with head and neck squamous cell carcinoma (HNSCC), which accounts for around 90% of all head and neck cancer. Especially in the more aggressive subtype of ...

Head and neck squamous cell carcinoma (HNSCC) remains a globally prevalent malignancy with high morbidity and mortality. Despite therapeutic advances, patient outcomes are hindered by tumor ...

Metabolic dysregulation is increasingly recognized as a driver of tumor progression, yet its specific role in head and neck squamous cell carcinoma (HNSCC) remains poorly characterized. This study ...

Prolonged overall survival (OS) was observed in heavily pre-treated refractory Head & Neck Squamous Cell Carcinoma (HNSCC) patients administered IV VCN-01 prior to the immune checkpoint inhibitor ...

Adding neoadjuvant and adjuvant pembrolizumab to the standard of care significantly improved event-free survival in patients with previously untreated, locally advanced head and neck squamous cell ...

A phase 2 study of ipatasertib in combination with pembrolizumab for first-line treatment of recurrent or metastatic squamous cell cancer of the head and neck. This is an ASCO Meeting Abstract from ...

VMPLNew Delhi [India], June 23: In one of oncology’s most anatomically complex regions, the difference between an accurate treatment plan and an imprecise one can be measured in millimetres, and felt ...

Researchers have reported results from the first-ever clinical trial of a new class of targeted therapy in pet cats with head and neck squamous cell carcinoma (HNSCC)—a cancer which is notoriously ...